{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T03:16:34Z","timestamp":1773717394818,"version":"3.50.1"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2020\/37\/B\/NZ7\/03499"],"award-info":[{"award-number":["2020\/37\/B\/NZ7\/03499"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.pbb.2025.173996","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T07:49:30Z","timestamp":1741333770000},"page":"173996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Coadministration of scopolamine and mGlu2 receptor negative allosteric modulator VU6001966 as a potential therapeutic approach for depression: Rat frontal cortex neurochemistry and behavior"],"prefix":"10.1016","volume":"250","author":[{"given":"Yana","family":"Babii","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Pa\u0142ucha-Poniewiera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystyna","family":"Go\u0142embiowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Bysiek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabela","family":"Szpr\u0119giel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Pilc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pbb.2025.173996_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2011.05.003","article-title":"Magnetic resonance imaging studies in unipolar depression: systematic review and meta-regression analyses","volume":"22","author":"Arnone","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.pbb.2025.173996_bb0010","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s43440-024-00630-4","article-title":"Subchronic administration of scopolamine reverses UCMS-induced behavior in mice via eEF2 protein dephosphorylation","volume":"76","author":"Babii","year":"2024","journal-title":"Pharmacol. Rep."},{"issue":"3","key":"10.1016\/j.pbb.2025.173996_bb0015","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ejphar.2007.11.028","article-title":"Do selective serotonin reuptake inhibitors acutely increase frontal cortex levels of serotonin?","volume":"580","author":"Beyer","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.pbb.2025.173996_bb0020","doi-asserted-by":"crossref","DOI":"10.1007\/BF00176837","article-title":"Is the forced swimming test a suitable model for revealing antidepressant activity?","volume":"94","author":"Borsini","year":"1988","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.pbb.2025.173996_bb0025","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2710.2000.00302.x","article-title":"Sequential improvement of anxiety, depression and anhedonia with sertraline treatment in patients with major depression","volume":"25","author":"Boyer","year":"2000","journal-title":"J. Clin. Pharm. Ther."},{"issue":"4","key":"10.1016\/j.pbb.2025.173996_bb0030","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.neuropharm.2003.10.009","article-title":"MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity","volume":"46","author":"Chaki","year":"2004","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.pbb.2025.173996_bb0035","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1176\/ajp.144.4.468","article-title":"Induction of depression with oxotremorine in patients with Alzheimer\u2019s disease","volume":"144","author":"Davis","year":"1987","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2025.173996_bb0040","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/BF02245592","article-title":"Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants","volume":"121","author":"Detke","year":"1995","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.pbb.2025.173996_bb0045","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/00008877-199611000-00009","article-title":"Estimation of in-vivo neurotransmitter release by brain microdialysis: the issue of validity","volume":"7","author":"Di Chiara","year":"1996","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pbb.2025.173996_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2021.173316","article-title":"Antidepressant-like actions of the mGlu2\/3 receptor antagonist TP0178894 in the chronic social defeat stress model: comparison with escitalopram","volume":"212","author":"Dong","year":"2022","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"12","key":"10.1016\/j.pbb.2025.173996_bb0055","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.biopsych.2006.02.013","article-title":"A neurotrophic model for stress-related mood disorders","volume":"59","author":"Duman","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2025.173996_bb0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jad.2014.03.010","article-title":"Antidepressant treatment history as a predictor of response to scopolamine: clinical implications","volume":"162","author":"Ellis","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pbb.2025.173996_bb0065","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320970325","article-title":"May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance","volume":"10","author":"Fava","year":"2020","journal-title":"Therapeutic Advances in Psychopharmacology"},{"issue":"2","key":"10.1016\/j.pbb.2025.173996_bb0070","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pnpbp.2009.11.018","article-title":"Elevated level of metabotropic glutamate receptor 2\/3 in the prefrontal cortex in major depression","volume":"34","author":"Feyissa","year":"2010","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"10","key":"10.1016\/j.pbb.2025.173996_bb0075","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archpsyc.63.10.1121","article-title":"Antidepressant efficacy of the Antimuscarinic drug scopolamine","volume":"63","author":"Furey","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.pbb.2025.173996_bb0080","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/da.22968","article-title":"Defining treatment-resistant depression","volume":"37","author":"Gaynes","year":"2020","journal-title":"Depress. Anxiety"},{"issue":"5","key":"10.1016\/j.pbb.2025.173996_bb0085","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2174\/18715273113129990079","article-title":"mGlu2\/3 agonist-induced hyperthermia: an in vivo assay for detection of mGlu2\/3 receptor antagonism and its relation to antidepressant-like efficacy in mice","volume":"12","author":"Gleason","year":"2013","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"2","key":"10.1016\/j.pbb.2025.173996_bb0090","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/026988119701100204","article-title":"Neuropsychological and neuroimaging evidence for the involvement of the frontal lobes in depression","volume":"11","author":"Goodwin","year":"1997","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.pbb.2025.173996_bb0095","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0028-3908(99)00166-5","article-title":"GABAB receptor antagonists elevate both mRNA and protein levels of the neurotrophins nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) but not neurotrophin-3 (NT-3) in brain and spinal cord of rats","volume":"39","author":"Heese","year":"2000","journal-title":"Neuropharmacology"},{"issue":"Suppl. 6","key":"10.1016\/j.pbb.2025.173996_bb0100","first-page":"4","article-title":"History and evolution of the monoamine hypothesis of depression","volume":"61","author":"Hirschfeld","year":"2000","journal-title":"J. Clin. Psychiatry"},{"issue":"7778","key":"10.1016\/j.pbb.2025.173996_bb0105","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(72)93021-8","article-title":"A cholinergic-adrenergic hypothesis of mania and depression","volume":"300","author":"Janowsky","year":"1972","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pbb.2025.173996_bb0110","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/archpsyc.1973.01750340072012","article-title":"Parasympathetic suppression of manic symptoms by physostigmine","volume":"28","author":"Janowsky","year":"1973","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2025.173996_bb0115","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.neuron.2019.09.044","article-title":"mGlu2 and mGlu3 negative allosteric modulators divergently enhance Thalamocortical transmission and exert rapid antidepressant-like effects","volume":"105","author":"Joffe","year":"2020","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.pbb.2025.173996_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-3223(92)90137-O","article-title":"Role of the dopaminergic system in depression","volume":"32","author":"Kapur","year":"1992","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2025.173996_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0028-3908(97)00191-3","article-title":"LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors","volume":"37","author":"Kingston","year":"1998","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.pbb.2025.173996_bb0130","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1038\/tp.2014.105","article-title":"Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression","volume":"4","author":"Lally","year":"2014","journal-title":"Transl. Psychiatry"},{"issue":"7586","key":"10.1016\/j.pbb.2025.173996_bb0135","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(69)91140-4","article-title":"Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect","volume":"293","author":"Lapin","year":"1969","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.pbb.2025.173996_bb0140","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.biopsych.2011.06.031","article-title":"Reduced right ventrolateral prefrontal cortex activity while inhibiting positive affect is associated with improvement in hedonic capacity after 8 weeks of antidepressant treatment in major depressive disorder","volume":"70","author":"Light","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2025.173996_bb0145","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/ph3010019","article-title":"The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments","volume":"3","author":"Machado-Vieira","year":"2010","journal-title":"Pharmaceuticals"},{"issue":"15","key":"10.1016\/j.pbb.2025.173996_bb0150","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1523\/JNEUROSCI.19-15-06629.1999","article-title":"Presynaptic regulation of glutamate release in the ventral tegmental area during morphine withdrawal","volume":"19","author":"Manzoni","year":"1999","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.pbb.2025.173996_bb0155","doi-asserted-by":"crossref","DOI":"10.2174\/1871527316666170309142646","article-title":"Further evaluation of mechanisms associated with the Antidepressantlike signature of scopolamine in mice","volume":"16","author":"Martin","year":"2017","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"1","key":"10.1016\/j.pbb.2025.173996_bb0160","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF00347089","article-title":"\u00dcber die depressogene Wirkung von Physostigmin","volume":"218","author":"Modestin","year":"1973","journal-title":"Archiv Fur Psychiatrie Und Nervenkrankheiten"},{"issue":"8","key":"10.1016\/j.pbb.2025.173996_bb0165","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1038\/s41380-022-01661-0","article-title":"The serotonin theory of depression: a systematic umbrella review of the evidence","volume":"28","author":"Moncrieff","year":"2023","journal-title":"Mol. Psychiatry"},{"issue":"7","key":"10.1016\/j.pbb.2025.173996_bb0170","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/s41380-018-0252-9","article-title":"Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies","volume":"24","author":"Moriguchi","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pbb.2025.173996_bb0175","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.nbd.2015.06.012","article-title":"Rapid antidepressant actions of scopolamine: role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors","volume":"82","author":"Navarria","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pbb.2025.173996_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108089","article-title":"Examining the role of muscarinic M5 receptors in VTA cholinergic modulation of depressive-like and anxiety-related behaviors in rats","volume":"171","author":"Nunes","year":"2020","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pbb.2025.173996_bb0185","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0165-1781(83)90043-4","article-title":"Behavioral, physiological, and neuroendocrine responses to arecoline in normal twins and \u201cwell state\u201d bipolar patients","volume":"9","author":"Nurnberger","year":"1983","journal-title":"Psychiatry Res."},{"issue":"5","key":"10.1016\/j.pbb.2025.173996_bb0190","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/0269881106069938","article-title":"The other face of depression, reduced positive affect: the role of catecholamines in causation and cure","volume":"21","author":"Nutt","year":"2007","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.pbb.2025.173996_bb0195","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00213-010-1978-5","article-title":"On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039","volume":"212","author":"Pa\u0142ucha-Poniewiera","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.173996_bb0200","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pnpbp.2017.06.022","article-title":"The involvement of monoaminergic neurotransmission in the antidepressant-like action of scopolamine in the tail suspension test","volume":"79","author":"Pa\u0142ucha-Poniewiera","year":"2017","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"10","key":"10.1016\/j.pbb.2025.173996_bb0205","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1111\/j.1460-9568.2007.05546.x","article-title":"Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell","volume":"25","author":"Paterson","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.pbb.2025.173996_bb0210","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1998"},{"key":"10.1016\/j.pbb.2025.173996_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2022.931964","article-title":"Encore: Behavioural animal models of stress, depression and mood disorders","volume":"16","author":"Petkovi\u0107","year":"2022","journal-title":"Front. Behav. Neurosci."},{"issue":"15\u201316","key":"10.1016\/j.pbb.2025.173996_bb0220","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1007\/s00213-016-4325-7","article-title":"Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats","volume":"233","author":"Podkowa","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.173996_bb0225","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.neuropharm.2016.08.031","article-title":"Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495","volume":"111","author":"Podkowa","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2025.173996_bb0230","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.neuropharm.2018.08.022","article-title":"The potential antidepressant action and adverse effects profile of scopolamine co-administered with the mGlu7 receptor allosteric agonist AMN082 in mice","volume":"141","author":"Podkowa","year":"2018","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.pbb.2025.173996_bb0235","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/ejn.12490","article-title":"Stress and VTA synapses: implications for addiction and depression","volume":"39","author":"Polter","year":"2014","journal-title":"Eur. J. Neurosci."},{"issue":"4","key":"10.1016\/j.pbb.2025.173996_bb0240","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0014-2999(78)90118-8","article-title":"Behavioural despair in rats: a new model sensitive to antidepressant treatments","volume":"47","author":"Porsolt","year":"1978","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.pbb.2025.173996_bb0245","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/01.ftd.0000168293.48226.57","article-title":"Pharmacokinetics and pharmacodynamics in clinical use of scopolamine","volume":"27","author":"Renner","year":"2005","journal-title":"Ther. Drug Monit."},{"issue":"1","key":"10.1016\/j.pbb.2025.173996_bb0250","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0165-0270(94)00132-Z","article-title":"Determination of in vivo amino acid neurotransmitters by high-performance liquid chromatography with o-phthalaldehyde-sulphite derivatisation","volume":"57","author":"Rowley","year":"1995","journal-title":"J. Neurosci. Methods"},{"issue":"1","key":"10.1016\/j.pbb.2025.173996_bb0255","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2011.07.036","article-title":"Towards a glutamate hypothesis of depression","volume":"62","author":"Sanacora","year":"2012","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.pbb.2025.173996_bb0260","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/cercor\/bhn134","article-title":"Quantitative analysis of the expression of dopamine D1 and D2 receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex","volume":"19","author":"Santana","year":"2009","journal-title":"Cereb. Cortex"},{"issue":"5","key":"10.1016\/j.pbb.2025.173996_bb0265","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1176\/ajp.122.5.509","article-title":"The catecholamine hypothesis of affective disorders: a review of supporting evidence","volume":"122","author":"Schildkraut","year":"1965","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2025.173996_bb0270","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.neulet.2016.01.057","article-title":"Ventral tegmental area muscarinic receptors modulate depression and anxiety-related behaviors in rats","volume":"616","author":"Small","year":"2016","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.pbb.2025.173996_bb0275","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0006-3223(96)00006-6","article-title":"The anatomy of mood disorders \u2014 review of structural neuroimaging studies","volume":"41","author":"Soares","year":"1997","journal-title":"Biol. Psychiatry"},{"issue":"7991","key":"10.1016\/j.pbb.2025.173996_bb0280","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(76)90562-6","article-title":"Depression associated with oral choline","volume":"308","author":"Tamminga","year":"1976","journal-title":"Lancet"},{"issue":"01","key":"10.1016\/j.pbb.2025.173996_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4236\/ojd.2019.81001","article-title":"Naltrexone and scopolamine rapidly reduce symptoms of major depressive disorder (MDD): a double blinded randomized controlled pilot study","volume":"08","author":"Taub","year":"2019","journal-title":"Open Journal of Depression"},{"issue":"3","key":"10.1016\/j.pbb.2025.173996_bb0290","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0165-0327(02)00306-3","article-title":"Assessing the effects of bupropion SR on mood dimensions of depression","volume":"78","author":"Tomarken","year":"2004","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.pbb.2025.173996_bb0300","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.bbr.2007.07.002","article-title":"Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats","volume":"184","author":"Winter","year":"2007","journal-title":"Behav. Brain Res."},{"issue":"2","key":"10.1016\/j.pbb.2025.173996_bb0305","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1124\/jpet.114.216804","article-title":"M1 and M2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine","volume":"351","author":"Witkin","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2025.173996_bb0310","series-title":"Involvement of muscarinic receptor mechanisms in antidepressant drug action","first-page":"311","author":"Witkin","year":"2020"},{"issue":"12","key":"10.1016\/j.pbb.2025.173996_bb0315","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.3390\/ijms23126713","article-title":"Effect of psilocybin and ketamine on brain neurotransmitters, glutamate receptors, DNA and rat behavior","volume":"23","author":"Wojtas","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pbb.2025.173996_bb0320","series-title":"Global Burden of Mental Disorders and the Need for a Comprehensive, Coordinated Response from Health and Social Sectors at the Country Level\u2013Report by the Secretariat","author":"World Health Organization","year":"2011"},{"issue":"9","key":"10.1016\/j.pbb.2025.173996_bb0325","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2174\/092986712799462630","article-title":"The role of glutamate signaling in pain processes and its regulation by GCP II inhibition","volume":"19","author":"Wozniak","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.pbb.2025.173996_bb0330","series-title":"Serotonin–Dopamine Interaction: Experimental Evidence and Therapeutic Relevance","first-page":"265","article-title":"Dynamics of the dopaminergic system as a key component to the understanding of depression","author":"Yadid","year":"2008"},{"issue":"22","key":"10.1016\/j.pbb.2025.173996_bb0335","doi-asserted-by":"crossref","first-page":"10037","DOI":"10.1073\/pnas.88.22.10037","article-title":"Interplay between glutamate and gamma-aminobutyric acid transmitter systems in the physiological regulation of brain-derived neurotrophic factor and nerve growth factor synthesis in hippocampal neurons","volume":"88","author":"Zafra","year":"1991","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"13","key":"10.1016\/j.pbb.2025.173996_bb0340","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1073\/pnas.1819540116","article-title":"2R,6R-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions","volume":"116","author":"Zanos","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"8","key":"10.1016\/j.pbb.2025.173996_bb0345","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1093\/cercor\/bhaa027","article-title":"Dopamine differentially regulates response dynamics of prefrontal cortical principal neurons and interneurons to optogenetic stimulation of inputs from ventral tegmental area","volume":"30","author":"Zhong","year":"2020","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.pbb.2025.173996_bb0350","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320938556","article-title":"The effects of intramuscular administration of scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled trial","volume":"10","author":"Zhou","year":"2020","journal-title":"Therapeutic Advances in Psychopharmacology"},{"issue":"6","key":"10.1016\/j.pbb.2025.173996_bb0355","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1093\/cercor\/bhaa399","article-title":"Divergent whole brain projections from the ventral midbrain in macaques","volume":"31","author":"Zubair","year":"2021","journal-title":"Cereb. Cortex"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305725000437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305725000437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T11:35:14Z","timestamp":1744025714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305725000437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":70,"alternative-id":["S0091305725000437"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2025.173996","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coadministration of scopolamine and mGlu2 receptor negative allosteric modulator VU6001966 as a potential therapeutic approach for depression: Rat frontal cortex neurochemistry and behavior","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2025.173996","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"173996"}}